<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01404676</url>
  </required_header>
  <id_info>
    <org_study_id>2010-02-053</org_study_id>
    <nct_id>NCT01404676</nct_id>
  </id_info>
  <brief_title>The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes</brief_title>
  <official_title>The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of vildagliptin based treatment versus sulfonylurea based treatment on glycemic
      variability, oxidative stress, and endothelial function in patients with type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently, improved understanding of the incretin effect on the pathophysiology of type 2
      diabetes has led to development of new agent for hypoglycemic therapy. Vildagliptin is a
      potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor that augments the active
      glucagon-like peptide(GLP)-1 concentration, increases insulin secretion and improves glucose
      tolerance. Vildagliptin has a similar glucose lowering effect, but lower hypoglycemic events,
      as compared to glimepiride. Vildagliptin could improve not only the mean glycemic control but
      also 24 hour glycemic fluctuation by restoring the physiologic pattern of insulin and
      glucagon secretion. Furthermore, decreased postprandial glycemic excursion might reduce the
      oxidative stress markers and improve endothelial dysfunction. Those effects might be
      amplified in Asian patients because of prominent early phase insulin secretory defects
      accompanied with relatively less degree of insulin resistance. In addition, GLP-1 and GLP-1
      analogues exert direct beneficial effects on endothelium-dependent vasodilatation. Therefore
      DPP-4 inhibitors may directly improve endothelial dysfunction.

      Based on this assumption, this research will focus on the effect of vildagliptin on glycemic
      variability, oxidative stress markers and endothelial cell function compared to long acting
      sulfonylurea glimepiride in type 2 diabetic patients with inadequate glycemic control on
      metformin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean amplitude of glycemic excursion(MAGE) for 12 weeks(12weeks - 0 week).</measure>
    <time_frame>0 week and 12 weeks</time_frame>
    <description>To compare the effect of vildagliptin based treatment for 12 weeks on glycemic variability with sulfonylurea using continuous glucose monitoring system(CGMS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in oxidative stress markers and inflammatory markers at 12 weeks. Change from baseline in endothelial cell function at 12 weeks.</measure>
    <time_frame>0 week and 12 weeks</time_frame>
    <description>To evaluate the change of oxidative stress markers and inflammatory markers from baseline.
To evaluate the change of endothelial cell function using high-resolution ultrasonography to measure brachial artery flow-mediated dilation (FMD) from baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Vildagliptin + Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adding Vildagliptin to metformin users</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepiride + Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adding Glimepiride to metformin users</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Add Vildagliptin</intervention_name>
    <description>Adding Vildagliptin 50 mg bid to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%</description>
    <arm_group_label>Vildagliptin + Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Add Glimepiride</intervention_name>
    <description>Adding Glimepiride 2mg to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%</description>
    <arm_group_label>Glimepiride + Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetic patients with hemoglobin A1c levels within the range 7% - 10%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moon-Kyu Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>June 22, 2010</study_first_submitted>
  <study_first_submitted_qc>July 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2011</study_first_posted>
  <last_update_submitted>September 14, 2018</last_update_submitted>
  <last_update_submitted_qc>September 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucose variability</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>Endothelial cell function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

